DaVita Inc. $DVA Shares Sold by Mirae Asset Global Investments Co. Ltd.

Key Points

• Mirae Asset Global Investments Co. Ltd. significantly reduced its stake in DaVita Inc. by 72.6%, selling over 17,000 shares during the second quarter, leaving them with 6,691 shares valued at approximately $953,000.
• DaVita reported an earnings per share (EPS) of $2.95 for the latest quarter, surpassing analyst expectations of $2.70, alongside a 6.1% increase in revenue year-over-year.
• Brokerages have mixed ratings on DaVita, with Wall Street Zen upgrading the stock to "buy," while others like Bank of America have downgraded it to "underperform" with a lowered price target.

Mirae Asset Global Investments Co. Ltd. decreased its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 72.6% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 6,691 shares of the company's stock after selling 17,697 shares during the period. Mirae Asset Global Investments Co. Ltd.'s holdings in DaVita were worth $953,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC raised its stake in shares of DaVita by 2.0% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after purchasing an additional 69 shares during the period. UMB Bank n.a. increased its stake in shares of DaVita by 65.5% in the first quarter. UMB Bank n.a. now owns 192 shares of the company's stock worth $29,000 after buying an additional 76 shares during the last quarter. Exchange Traded Concepts LLC increased its stake in shares of DaVita by 8.9% in the first quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock worth $148,000 after buying an additional 79 shares during the last quarter. Mather Group LLC. increased its stake in shares of DaVita by 7.0% in the first quarter. Mather Group LLC. now owns 1,201 shares of the company's stock worth $184,000 after buying an additional 79 shares during the last quarter. Finally, National Pension Service increased its stake in shares of DaVita by 74.3% in the first quarter. National Pension Service now owns 197 shares of the company's stock worth $30,000 after buying an additional 84 shares during the last quarter. Hedge funds and other institutional investors own 90.12% of the company's stock.

DaVita Trading Down 1.2%

Shares of DaVita stock opened at $126.33 on Friday. The company's 50-day moving average price is $133.55 and its two-hundred day moving average price is $139.51. DaVita Inc. has a 52 week low of $126.07 and a 52 week high of $179.60. The stock has a market cap of $9.03 billion, a PE ratio of 12.42, a price-to-earnings-growth ratio of 0.92 and a beta of 1.13.

DaVita (NYSE:DVA - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $2.95 EPS for the quarter, topping the consensus estimate of $2.70 by $0.25. DaVita had a net margin of 6.35% and a return on equity of 369.39%. The firm had revenue of $3.38 billion for the quarter, compared to analysts' expectations of $3.36 billion. During the same period in the previous year, the business earned $2.00 earnings per share. DaVita's revenue for the quarter was up 6.1% compared to the same quarter last year. DaVita has set its FY 2025 guidance at 10.200-11.300 EPS. On average, equities analysts predict that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on DVA. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Saturday, September 13th. Truist Financial set a $148.00 price target on shares of DaVita in a research note on Friday, August 8th. Weiss Ratings reaffirmed a "hold (c+)" rating on shares of DaVita in a report on Wednesday. Bank of America decreased their price objective on shares of DaVita from $145.00 to $140.00 and set an "underperform" rating for the company in a report on Wednesday, September 10th. Finally, Barclays decreased their price objective on shares of DaVita from $160.00 to $149.00 and set an "equal weight" rating for the company in a report on Thursday. Four research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, DaVita has a consensus rating of "Reduce" and an average target price of $155.25.

Insider Buying and Selling

In other DaVita news, insider James O. Hearty sold 2,351 shares of the business's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $150.00, for a total value of $352,650.00. Following the sale, the insider directly owned 26,038 shares in the company, valued at approximately $3,905,700. The trade was a 8.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.50% of the company's stock.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.